Justin Yap

Justin Yap is also an Executive Director of CathRx Limited, an Australian medical device company commercialising novel cardiac electrophysiology catheters for the treatment of heart rhythm disorders. He is a Non-Executive Director of Hexima Limited, a biotechnology company actively engaged in the research and development of plant-derived proteins and peptides for applications as human therapeutics and for the genetic modification of crops. Prior to this, he began his career in investment banking for Mosaic Risk Management Pty Ltd, a wholly owned subsidiary of Wilson HTM Limited specialising in derivatives risk management.